Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.